2023 | Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study | Oh, Do-Youn; Algazi, Alain; Capdevila, Jaume; Longo, Federico; Miller, Wilson; Chun Bing, Jerry Tan; Bonilla, Carlos Eduardo; Chung, Hyun Cheol; Guren, Tormod K; CHIA-CHI LIN ; Motola-Kuba, Daniel; Shah, Manisha; Hadoux, Julien; Yao, Lili; Jin, Fan; Norwood, Kevin; Lebellec, Loïc | Cancer | 5 | 3 | |
2023 | Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 | Satake, Hironaga; Lee, Keun-Wook; Chung, Hyun Cheol; Lee, Jeeyun; Yamaguchi, Kensei; Chen, Jen-Shi; Yoshikawa, Takaki; Amagai, Kenji; KUN-HUEI YEH ; Goto, Masahiro; Chao, Yee; Lam, Ka-On; Han, Shi Rong; Shiratori, Shinichi; Shah, Sukrut; Shitara, Kohei | Japanese journal of clinical oncology | 1 | 0 | |